Pipeline

KONDREE holds a unique worldwide expertise in the management of pathological oxidative stress by offering combined software and molecular products.
This innovative approach forms the foundation of our research and therapeutic development. It enables us to explore new avenues for the treatment of diseases affected by oxidative stress, specifically for rare diseases and Aging with the goal of providing patients with innovative and effective therapies.

We offer therapeutic solutions based on an accelerated clinical trial model, made possible by a specific type of study and an optimized timeline.

This approach is built on:

  • A 1-year observational clinical study, enabling precise patient biological
  • A 2-year clinical trial program, structured as follows:
    • 6 months of fixed dosages,
    • followed by 18 months of adjusted dosages to maximize efficacy and treatment personalization.

Thanks to this innovative strategy, go-to-market can be achieved in 5 years, compared with approximately 15 years for a traditional biotech development model.